Vesugen is strictly for laboratory research and is commonly employed in the following investigational areas:

Vasoprotection and Atherosclerosis

Research models utilize Vesugen to evaluate its vasoprotective activity. Investigations focus on the peptide’s effects during the progression of atherosclerosis and restenosis, quantifying changes in vascular wall integrity, cellular responses to injury, and the mitigation of age-related vascular decline.

Neuroprotection and Alzheimer’s Disease

Experimental protocols employ this peptide to characterize its neuroprotective properties. Studies assess the protection of fibroblast-derived induced neurons from age-related changes and investigate its regulatory mechanisms in the context of Alzheimer’s disease prevention and treatment models.

Geroprotection and Aging

In gerontological research, Vesugen is used to study the broader peptide regulation of aging. Researchers evaluate how short peptides influence cellular senescence, maintain tissue homeostasis, and modulate biological age markers over extended experimental timelines.

Pathway / Mechanistic Context

The primary mechanism of action for Vesugen in research settings involves its function as a short peptide bioregulator, modulating cellular pathways associated with vascular and neuronal tissue aging.

• Vasoprotective Signaling: Interacts with vascular tissues to mitigate the molecular and pathophysiological processes associated with atherosclerosis and restenosis.
• Neuroprotective Modulation: Modulates pathways that protect induced neurons from age-related structural and functional decline.
• Geroprotective Regulation: Influences cellular activity and potentially gene expression to counteract fundamental mechanisms of aging and cellular senescence.

Preclinical Research Summary

Published preclinical literature documents investigations of Vesugen across various experimental models focusing on aging and tissue protection.

• In neuronal models, Vesugen (KED) has been shown to protect fibroblast-derived induced neurons from age-related changes.
• Research indicates potential applications for peptide drugs like Vesugen in the experimental prevention and treatment paradigms of Alzheimer’s disease.
• Studies on atherosclerosis and restenosis have characterized the specific molecular aspects of the KED peptide’s vasoprotective activity.
• Broader investigations highlight the role of such bioregulators in the overarching peptide regulation of aging.

Form & Analytical Testing

• Solid-Phase Peptide Synthesis
• Lyophilization
• Identity Verification: Mass Spectrometry (MS) to confirm molecular weight and identity.
• Purity Verification: High-Performance Liquid Chromatography (HPLC) is performed to ensure the product meets the purity standard.

Referenced Citations

References are provided for informational purposes only and are not clinical claims.

• Kraskovskaya, N., et al. (2024). Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes. MDPI AG. https://doi.org/10.3390/ijms252111363
• Ryzhak, G. A., & Ilina, A. R. (2025). Prospects of using peptide drugs for the prevention and treatment of Alzheimer’s disease. Autonomous non-profit organization-Society of Specialists in the Field Innovative Medical Technology. https://doi.org/10.37586/2949-4745-4-2024-223-226
• Kozlov, K., et al. (2016). [Molecular aspects of vasoprotective peptide KED activity during atherosclerosis and restenosis]. Advances in gerontology = Uspekhi gerontologii, 29(4), 646–650.
• Arutjunyan, A. V., Popovich, I. G., Kozina, L. S., & Ryzhak, G. A. (2025). Peptide Regulation of Ageing: From Experiment to Practice. Bentham Science Publishers Ltd. https://doi.org/10.2174/0118746098346230250116065407
• Khavinson, V. Kh. (2020). Peptide medicines: past, present, future. Medical Informational Agency Publishers. https://doi.org/10.30629/0023-2149-2020-98-3-165-177

• Stable at room temperature for up to 90 days. For long-term storage, keep at -20°C (-4°F) or colder.
• Once mixed with a solvent (e.g., bacteriostatic water), the solution must be stored at 4 °C (39°F) and utilized within 30 days. Avoid repeated freeze-thaw cycles, as this degrades the peptide structure.

RESEARCH USE ONLY

This product is intended strictly for laboratory research use only. It is not for human or veterinary use. It is not intended for diagnosis, treatment, cure, or prevention of any disease. All purchases are subject to our Terms of Service and Purity Guarantee.

No COAs available for this product.